An Open Trial to Assess the Tolerability of AVANZ® Salsola Immunotherapy

Summary

This trial is an open, national, multi-centre trial. The trial will be initiated in December 2013 and subjects will receive treatment for 6 weeks. Safety monitoring will be performed in an ongoing basis through a Clinical Safety Group with immediate access to Adverse Events registered in the clinical database. The composition, procedures and deliverables of the Clinical Safety Group will be detailed in a Safety Agreement prior to trial start.

Timeline

Start

2013-12

Primary completion

2014-08

Completion

2014-12

Drugs

Indications